Iranian Journal of Allergy, Asthma and Immunology 2017. 16(1):28-38.

Anti-inflammatory Effects of Novel Thiazolidinone Derivatives as Bioactive Heterocycles on RAW264.7 Cells
Hossein Ghafoori, Mehrnaz Rezaei, Asadollah Mohammadi


The inhibition of the inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2) and nuclear factor-κB (NF-κB) production are research targets of attract in the field of anti-inflammatory drug development. Therefore, this study was designed to investigate the anti-inflammatory effects of novel thiazolidinone derivatives using a cellular model of lipopolysaccharide (LPS)-stimulated murine macrophage RAW 264.7. In the present study, five new derivatives (A to E) of thiazolidinone were synthesized and screened for anti-inflammatory activities. Cell viability of LPS-stimulated RAW 264.7 macrophages clearly decreased in >55 μg/mL of synthesized A-E compounds especially in the presence of C; therefore, up to 50 μg/mL of compounds were selected for the subsequent analysis. A majority of these compounds showed significant inhibition on the production of NO in LPS-stimulated macrophages in a dose-dependent manner. Compounds B and D (10-50 μg/mL) significantly inhibited LPS-induced NF-κB (p65) production in a dose-dependent manner. The effects of B and D on iNOS and COX-2 mRNA and protein expression in LPS-stimulated RAW 264.7 cells were detected by real time-PCR and western blot. B derivative significantly suppressed the iNOS and COX-2 mRNA level and as well as protein expression. Taken together, these results reveal that compound B as new thiazolidinone derivative decreased expression of the inflammatory-related signals (NO, iNOS and COX-2) through regulation of NF-κB; hence, this compound could be suggested as a novel therapeutic strategy for inflammation-associated disorders.


Anti-inflammatory effects; COX-2; iNOS; NF-κB (p65); Thiazolidinone

Full Text:



1. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124(2):263-6.

2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917):860-7.

3. Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol 2005; 2(2):90-7.

4. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431(7007):461-6.

5. Lee HJ, Hyun E-A, Yoon WJ, Kim BH, Rhee MH, Kang HK, et al. In vitro anti-inflammatory and anti-oxidative effects of Cinnamomum camphora extracts. JJ Ethnopharmacol 2006; 103(2):208-16 .

6. Roumen RMH, Redl H, Schlag G, Zilow G, Sandtner W,Koller W, et al. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit Care Med 1995; 23(3):474-80.

7. Epstein FH, Barnes PJ, Karin M. Nuclear factor- B a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15):1066-71.

8. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle.Cell 2002; 109(2):S81-S96.

9. Hayden MS, Ghosh S. Signaling to NF-kB. Genes Dev2004; 18(18):2195-224.

10. Viatour P, Merville M-P, Bours V, Chariot A.Phosphorylation of NF-kB and proteins implications in cancer and inflammation. Trends Biochem Sci 2005;30(1):43-52.

11. Sacca R, Cuff CA, Ruddle NH. Mediators of inflammation. Curr Opin Immunol 1997; 9(6):851-7.

12. Surh YJ, Chun KS, Cha H-H, Han SS, Keum YS, ParkKK, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kB activation. Mutat Res2001; 480:243-68.

13. Larsen GL, Henson PM. Mediators of inflammation.Annu Rev Immunol 1983; 1(1):335-59.

14. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16(1):225-60.

15. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72(11):1605-21.

16. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18(1):3-10.

17. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6(12):3051-64.

18. MacMicking J, Xie Q-w, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15(1):323-50.

19. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89(12):2637-45.

20. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1(1):11-21.

21. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353(9149):307-14.

22. Psaty BM, Furberg CD. COX-2 inhibitors lessons in drug safety. N engl J med 2005; 352(11):1133-5.

23. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339(6116):166-72.

24. Portenoy RK, Lesage P. Management of cancer pain.Lancet 1999; 353(9165):1695-700.

25. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14):1531-6.

26. Martins P, Jesus J, Santos S, Raposo LR, Roma- Rodrigues C, et al. Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box. Molecules 2015; 20:16852-16891

27. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg Med Chem 2012; 20(11):3378-95.

28. Jain VS, Vora DK, Ramaa CS. Thiazolidine-2, 4-diones: Progress towards multifarious applications. Bioorg Med Chem 2013; 21(7):1599-620.

29. Abhinit M, Ghodke M, Pratima NA. Exploring potential of 4-thiazolidinone: a brief review. Int J Pharm Pharm Sci 2009; 1(1):47-64.

30. Hu J, Wang Y, Wei X, Wu X, Chen G, Cao G, et al.Synthesis and biological evaluation of novel thiazolidinone derivatives as potential anti-inflammatory agents. Eur J Med Chem 2013; 64:292-301.

31. Sharma A, Kumar V, Jain S, Sharma PC. Thiazolidin-4- one and hydrazone derivatives of capric acid as possible anti-inflammatory, analgesic and hydrogen peroxide- scavenging agents. J Enzyme Inhib Med Chem 2011;26(4):546-52.

32. Ottana R, Mazzon E, Dugo L, Monforte F, Maccari R, Sautebin L, et al. Modeling and biological evaluation of 3-(1, 2-ethanediyl) bis [2-(4-methoxyphenyl)-thiazolidin-4-one], a new synthetic cyclooxygenase-2 inhibitor. Eur J Pharmacol 2002; 448(1):71-80.

33. Mohammadi A, Ghafoori H, Ghalami-Choobar B, Rohinejad R. Synthesis, solvatochromic properties and biological evaluation of some novel azo-hydrazone tautomeric dyes. Journal of Molecular Liquids 2014;198:44-50.

34. Mohammadi A, Safarnejad M. Synthesis, structural characterization and tautomeric properties of some novel bis-azo dyes derived from 5-arylidene-2, 4- thiazolidinone. Spectrochim Acta A Mol Biomol Spectrosc 2014; 126:105-11.

35. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005; 11:127-52.

36. Kim HK, Cheon BS, Kim YH, Kim SY, Kim HP. Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure activity relationships. Biochem Pharmacol 1999; 58(5):759-65.

37. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 1996; 236(2):302-8.

38. Nathan C. Points of control in inflammation. Nature 2002; 420(6917):846-52.

39. Makarov SS. NF- B as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 2000;6(11):441-8.

40. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107(2):135-42.

41. Hotamisligil GkS. Inflammation and metabolic disorders.Nature 2006; 444(7121):860-7.

42. Bhatti RS, Shah S, Krishan P, Sandhu JS. Recent Pharmacological Developments on Rhodanines and 2, 4- Thiazolidinediones. Int J Med Chem 2013; 2013:793260.

43. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 2001; 69(4):598-604.

44. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-k B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1. Nature 2008; 453(7196):807-11.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.